DrugBiological
Immunoglobulin G clinical trials
- studies test it
- 31
- open now
- 2
- in phase 3
- 16
- first study started
- 1999
Keep track of what changes. Save the Immunoglobulin G studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
31 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2003 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 8
- Phase 3
- 16
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 5
Nihon Pharmaceutical Co., Ltd (7) · Baxalta now part of Shire (5) · Octapharma (5) · Green Cross Corporation (3) · Takeda (2) · Genentech, Inc. (1) · Sutter Health (1) · Proclara Biosciences, Inc. (1)
Often tested with
Tested in the same studies.
Immunoglobulins, Intravenous (22) · Hyaluronoglucosaminidase (8) · Immunoglobulins (1)
Studies
Open first, then newest update. How each study uses Immunoglobulin G is read from its arms, and is right about nine times in ten.
Testing it · 31
- Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaRecruitingPhase 1/2M. Peter MarinkovichNCT06834035Written as Immunoglobulin G
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)RecruitingPhase 3TakedaNCT06747351Written as HYQVIA
- A Study of TAK-881 and HyQvia in Healthy AdultsCompletedPhase 1TakedaNCT06895967Written as HyQvia
- A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection ConditionsCompletedPhase 1Genentech, Inc.NCT07025577Written as Immunoglobulin G
- Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPCompletedPhase 3Baxalta now part of ShireNCT02955355Written as HYQVIA
- A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult ParticipantsCompletedPhase 1Baxalta now part of ShireNCT04578535Written as HYQVIA
- Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD SubjectsCompletedPhase 3Baxalta now part of ShireNCT03277313Written as HYQVIA
- A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedPhase 1/2GenmabNCT04424641Written as GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedPhase 3Baxalta now part of ShireNCT02549170Written as HYQVIA
- Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsCompletedPhase 4Baxalta now part of ShireNCT03116347Written as HYQVIA
- Phase III Clinical Study of NPB-01 in Patients With Autoimmune EncephalitisStatus unknownPhase 3Nihon Pharmaceutical Co., LtdNCT05177939Written as NPB-01
- Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive ImpairmentCompletedPhase 2Sutter HealthNCT01300728Written as NewGam 10% IVIG
- Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) NeuropathyCompletedPhase 3OctapharmaNCT02638207Written as NewGam
- Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:CompletedPhase 2Green Cross CorporationNCT04175522Written as Immunoglobulin G
- Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's DiseaseCompletedPhase 1Proclara Biosciences, Inc.NCT03008161Written as NPT088
- Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)CompletedPhase 2Johannes JakobsenNCT02556437Written as HyQvia
- A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody DeficiencyCompletedPhase 4Bio Products LaboratoryNCT02247154Written as Vigam® (Human Normal Immunoglobulin)
- Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune ThrombocytopeniaCompletedPhase 3OctapharmaNCT01349790Written as NewGam
- Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.CompletedPhase 2Nihon Pharmaceutical Co., LtdNCT01845584Written as NPB-01
- Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeCompletedPhase 3Nihon Pharmaceutical Co., LtdNCT02221271Written as NPB-01
See all 31 studies that test Immunoglobulin G →
Given in every arm · 3 — Immunoglobulin G is usual care beside what is tested
- A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency DiseasesCompletedPhase 2/3TakedaNCT05755035Written as HYQVIA
- Immune Globulin Subcutaenous (Human), 20%CompletedPhase 2/3Baxalta now part of ShireNCT01412385Written as Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
- Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki DiseaseCompletedPhase 4Green Cross CorporationNCT04003844Written as Immunoglobulin G
Codes
What other systems call Immunoglobulin G · ClinicalTrials.gg INT007648
- MeSH (NLM) D007074Immunoglobulin GOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007074 | Immunoglobulin G | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.